High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria

Summary

Paroxysmal Nocturnal Haemoglobinuria (PNH) results in a marked thrombophilic state by unknown mechanisms. Geographic differences in thrombosis incidence in PNH have been observed. We have reviewed 64 patients with “Classic PNH” from a single institution in order to determine the rate of thrombosis in different ethnic groups.When we compared African- Americans (n=11) and Latin-Americans (n=8) with other patients (n= 45), we found that African-American and Latin-American patients are at increased risk [Hazard ratio 3.66 (p=0.005) and 3.52, (p= 0.035) respectively by Cox regression]. Our data also suggest that this difference in the rate of thrombosis has an impact on length of survival.These findings demonstrate that ethnicity is a risk factor for thrombosis in PNH and have implications for decision-making regarding the management of these patients,including the prevention of thrombosis.

 

MissingLinkText

Keywords

Paroxysmal Nocturnal Hemoglobinuria (PNH) - ethnicity - thrombosis - hypercoagulable states - deep venous thrombosis

 

 

MissingLinkText

• References

• 1 Rotoli B, Luzzato L. Paroxysmal Nocturnal Hemoglobinuria. Bailliere's Clin Hematol 1989; 2: 118-38.
• 2 Socie G, Mary JY, de Gramont A et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996; 348: 573-7.
• 3 Hillmen P, Lewis SM, Bessler M. et al Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-8.
• 4 Ronne E, Pappot H, Grondahl-Hansen J. et al The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-81.
• 5 Nicholson-Weller A, Spicer DB, Austen KF. Deficiency of the complement regulatory protein, „decayaccelerating facor" on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinura. N Engl J Med 1985; 1091-7.
• 6 Jin JY, Tooze JA, Marsh JCW. et al Glycosylphosphatidyl- inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paoxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Br J Haematol 1997; 96: 493-6.
• 7 Polley MJ, Nachman RL. Human complement in thrombin-mediated platelet function. J Exp Med 1979; 150: 633-45.
• 8 Zimmerman TS, Kolb WP. Human platelet-initiated formation and uptake of the C5–9 complex of human complement. J Clin Invest 1976; 57: 203-11.
• 9 Dixon RH, Rosse WF, Thorpe AM. Mechanism of complement-mediated activation of human blood platelets in vitro. J Clin Invest 1977; 59: 360-8.
• 10 Devine DV, Siegel RSRWF. Interactions of the platelets in paroxysmal noctunral hemoglobinuria with complement J Clin Invest 1987; 79: 131-7.
• 11 Wiedmer J, Hall SE, Ortel TL. et al Complement- Induced Vesiculation and Exposure of Membrane Prothrombinase Sites in Platelets of Paroxysmal Nocturnal Hemoglobinuria. Blood 1993; 82: 1192-6.
• 12 Hugel B, Socie G, Vu T. et al Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
• 13 Sims PJ, Faioni EM, Wiedmer T. et al Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
• 14 Ott I, Miyagi Y, Miyazaki K. et al Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vascular Biol 2000; 20: 874-82.
• 15 Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria New Engl J Med. 1991; 325: 991-6.
• 16 Tudela M, Jarque I, Perez-Sirvent ML. et al Clinical profile and course of paroxysmal nocturnal hemoglobinuria. Sangre 1993; 38: 301-7.
• 17 Koduri PR, Gowrishnakar S. Paroxysmal nocturnal haemoglobinuria in Indians. Acta Haemtologica 1992; 88: 126-8.
• 18 Xio-feng L, Tian-ying Y, Xue-yon Y. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Chin Med J 1990; 103: 885-9.
• 19 Gongora-Biachi RA, Gonzalez-Martinez P, Sosa-Munoz J. et al Natural history of paroxysmal nocturnal hemoglobinuria in adolescents, adults, and children: the Mexican experience. Sangre 1997; 42: 171-7.
• 20 Krutrachue M, Wasi P, Na-Nakorn S. Paroxysmal Nocturnal Haemoglobinuria in Thailand with special reference to an association with aplastic anaemia. Br J Haematol 1978; 39: 267-76.
• 21 Fujioka S, Asai T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Acta Haematologica Japonica 1989; 52: 1386-94.
• 22 Araten DJ, Bessler M, McKenzie S. et al Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia 2002; 2243-8.
• 23 Antin JH, Ginsburg D, Smith BR. et al Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Blood 1985; 66: 1247-50.
• 24 Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102: 3587-91.
• 25 McMullin MF, Hillmen P, Jackson J. et al Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. J Intern Med 1994; 235: 85-9.
• 26 Stein PD, Kayali F, Olson RE. Regional differences in rates of diagnosis and mortality of pulmonary thromboembolism. Am J Cardiol 2004; 93: 1194-7.
• 27 Stein PD, Kayali F, Olson RE. et al Pulmonary thromboembolism in Asians/Pacific islanders in the United States: Analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116: 435-42.